High-Purity IVT RNA Compositions Without dsRNA Contaminants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing in vitro-transcribed (IVT) mRNA for therapeutic use are compromised by the presence of contaminants such as reverse complement transcription products and cytokine-inducing RNA, leading to immune activation and reduced integrity of the desired ssRNA product.
Innovation Solution
The development of novel IVT RNA synthesis methods that control the production of contaminants from the outset, resulting in compositions that are substantially free of reverse complement transcription products and cytokine-inducing RNA, with purity levels maintained through precise control of reaction conditions and avoidance of additional purification steps like RNase III treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If RNase III treatment is used to remove dsRNA contaminants from IVT mRNA, then dsRNA levels are reduced, but the integrity of the desired ssRNA product is compromised
Solution Approach 1:
The patent uses HPLC purification to selectively extract and remove dsRNA contaminants from IVT mRNA preparations without affecting the integrity of the desired ssRNA product. This extraction approach separates the harmful dsRNA components from the therapeutic ssRNA while maintaining product quality.
Solution Approach 2:
The patent employs HPLC as an intermediary purification method between IVT transcription and therapeutic application. This intermediary step selectively removes dsRNA contaminants through chromatographic separation based on hydrophobicity differences, allowing the desired ssRNA to pass through unchanged while trapping dsRNA contaminants on the column.
2Object-affected harmful factors
If HPLC purification is applied to remove dsRNA contaminants, then IFN and inflammatory cytokine levels are reduced, but translation efficiency may be affected by additional processing steps
Solution Approach 1:
The patent optimizes HPLC parameters including gradient profiles, buffer compositions, and flow rates to achieve effective dsRNA removal while minimizing impact on ssRNA translation efficiency. By carefully controlling these parameters, the method reduces IFN and cytokine induction without requiring excessive purification complexity.
3Productivity
If unmodified mRNA is used for therapeutic applications, then translation efficiency is improved, but high levels of cytokine secretion are induced
Solution Approach 1:
The patent extracts and removes the harmful component (dsRNA contaminants that trigger cytokine secretion) from unmodified mRNA preparations through HPLC purification. This allows the mRNA to maintain its high translation efficiency while the contaminant responsible for cytokine induction is selectively removed.
Solution Approach 2:
The patent uses the presence of dsRNA contaminants as a diagnostic marker to guide purification optimization. By monitoring dsRNA levels and their correlation with cytokine induction, the method converts the harmful contaminant into a useful indicator for optimizing HPLC conditions to achieve both high translation efficiency and low immunogenicity.
Data Source
AI summary
The invention relates to improved RNA compositions for use in therapeutic applications. The RNA compositions are particularly suited for use in human therapeutic application (e.g., in RNA therapeutics). The RNA compositions are made by improved processes, in particular, improved in vitro-transcription (IVT) processes. The invention also relates to methods for producing and purifying RNA (e.g, therapeutic RNAs), as well as methods for using the RNA compositions and therapeutic applications thereof.